Gunderson Dettmer advised Parallel Bio on the deal.Parallel Bio, a biotechnology company, announced its $4.3 million seed round led by Refactor Capital. Parallel Bio created a human…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
